QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States.
about
Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor TherapyWhat is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.Risk of infections associated with biological treatment in inflammatory bowel disease.Utility of in vitro interferon-γ release assay in differential diagnosis between intestinal tuberculosis and Crohn's disease.The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report.Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis.Infectious and malignant complications of TNF inhibitor therapy in IBD.Opportunistic infections due to inflammatory bowel disease therapy.Diagnosis and Management of Latent Tuberculosis Infection.Tuberculosis screening using IGRA and chest computed tomography in patients with inflammatory bowel disease: A retrospective study.Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study.Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients.Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases.Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients.UEG Week 2015 Poster Presentations
P2860
Q27005716-CEA1D9E0-099F-42A0-97D0-4165869BFECBQ27687191-B626BF8C-C2F4-4A71-9866-3092B8D6E7BCQ33882852-3E43B0D7-D5FF-4AF7-BDBE-E62E12F876C1Q34552028-25BB4504-8936-4507-82A0-683639A90BD5Q34645651-5C201D1B-39D6-4BEF-A24C-92537C2314A5Q35028459-411A3BD0-90E6-44F8-A7C5-06E80F71A21BQ36249147-CC579AF5-ECB3-4362-9D27-2D4396A33DE0Q37467519-47EC53D2-30AC-4521-B52A-FAA5EB2BA91DQ37980410-6EF5A7AD-05AC-421C-8E50-BB2C9F3108A2Q38138343-5336F30C-8278-4CFA-9D4E-0724D5F699F8Q38139812-610463AE-2449-4D2E-BA4B-BD9703DD1DF5Q38520964-7B18BF75-A203-439A-976C-794D9E61DF93Q40397823-9C4A54CE-2A27-4C2F-9D62-86A5397987C8Q41549099-34CEE8F2-652A-4944-BDD7-0AC0B5C63EDEQ41702217-193D74D1-5187-4E71-8118-3399FCEED81BQ42200253-3CFD4226-3B42-4461-B939-3CF5147A4275Q42276425-7410D030-EBC8-4F3E-96C4-DF498A3B6772Q45095583-651D64D9-9DE8-4275-9F35-3F293B2E453CQ47258498-189C813F-1771-4F08-BD31-DB29BFF8291BQ47652162-27B9CFC1-5DB2-4C43-AFEF-50763E5B703CQ49821178-CB9C8BEB-D75B-4665-81B8-70F043F406EAQ50098797-9E7327F3-1113-463C-9E01-94C97E729787Q50957661-CBB6B1E8-1B9E-4332-82D4-700326F60D8FQ53648894-A5F6FE72-6C28-41CB-BB6D-B53858B2587CQ56934656-E082476F-07A3-4DE7-A57D-28DA8C2B8609
P2860
QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
QuantiFERON TB gold testing fo ...... e cohort in the United States.
@en
QuantiFERON TB gold testing fo ...... e cohort in the United States.
@nl
type
label
QuantiFERON TB gold testing fo ...... e cohort in the United States.
@en
QuantiFERON TB gold testing fo ...... e cohort in the United States.
@nl
prefLabel
QuantiFERON TB gold testing fo ...... e cohort in the United States.
@en
QuantiFERON TB gold testing fo ...... e cohort in the United States.
@nl
P2093
P2860
P921
P356
P1476
QuantiFERON TB gold testing fo ...... e cohort in the United States.
@en
P2093
Ashwin N Ananthakrishnan
Bashar J Qumseya
David G Binion
Lilani Perera
Mazen Issa
Michael Bonner
Sue Skaros
Yelena Zadvornova
P2860
P356
10.1002/IBD.21329
P577
2011-01-01T00:00:00Z